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Gene expression profiles and risk stratification in
childhood acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) inchildren is a heterogeneous diseasewith a varied response to treatment.
Despite overall survival rates approaching
75-80%, a significant fraction of patients
still cannot be cured.1 Because of this het-
erogeneity, accurate assignment of patients
to different risk groups at the earliest time
possible is important in order to select the
best strategy for each individual.
Current risk stratification into standard-
(low-), intermediate- or high-risk groups is
based on molecular/cytogenetic markers
(BCR-ABL and MLL-AF4 rearrangements)
and the in vivo response to treatment.
Chromosomal aberrations frequently
involve non-random chromosomal translo-
cations that produce novel gene fusions or
lead to inappropriate expression of onco-
genes.2,3 These genetic alterations have a
clear impact on the patient’s prognosis as
exemplified by the association of Philadel-
phia chromosome positive ALL with a poor
outcome.4,5 Because of the significance of
cytogenetic abnormalities such as t(9;22),
t(1;19), t(12;21), and rearrangement of the
MLL gene on chromosome 11q23, great
efforts have been made recently to estab-
lish gene expression profiles that discrimi-
nate among these subtypes.6-11 Intriguingly,
distinct expression profiles that can accu-
rately predict cytogenetic subgroups have
indeed been identified in these studies.
A patient’s initial response to treatment,
which can be monitored with molecular
biology techniques, is one of the strongest
indicators of subsequent prognosis.12-14
Polymerase chain reaction (PCR)-based
analysis of minimal residual disease (MRD)
can detect residual leukemic cells during
induction therapy down to a level of one
leukemic cell in 105 normal cells. Given the
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Background and Objectives. Childhood acute lymphoblastic leukemia (ALL) is a het-
erogeneous disease. There are several distinct genetic subtypes, characterized by typical
changes in gene expression pattern. In addition to cytogenetic markers, the in vivo
response to treatment is an emerging prognostic marker for risk stratification. However,
it has not yet been reported whether gene expression profiles can predict risk group
stratification already at the time of diagnosis. 
Design and Methods. We analyzed bone marrow samples of 31 ALL patients to iden-
tify changes in gene expression that are associated with the current risk assignment,
irrespective of the genetic subtype. Gene expression profiles were established using
oligonucleotide microarrays. 
Results. Considering all low- and high-risk patients, no gene was capable of predict-
ing the risk assignment already at time of diagnosis. However, screening for risk group
associated genes using more homogeneous subsets of patients revealed 106 discrimina-
tory probe sets. The prognostic significance of these probe sets was subsequently deter-
mined for the entire series of patients. Using the selected subgroups as the training set
and the remaining samples as an independent test set, logistic regression using 3 pre-
dictor variables could accurately predict current risk assignment for 10 out of 12
patients. 
Interpretation and Conclusions. Gene expression profiles established from a cytoge-
netically heterogeneous study group are not, as yet, sufficiently accurate to be used
prognostically in a clinical setting. Additional risk-associated gene expression analyses
need to be performed in more homogeneous sets of patients.  
Key words: childhood acute lymphoblastic leukemia, gene expression, microarray,
risk stratification.
A B S T R A C T
Acute Lymphoblastic Leukemia • Research Paper
  
high prevalence in B-cell precursor and T-cell
leukemias, clonal T-cell receptor and/or immunoglobu-
lin chain rearrangements are the most suitable targets
for this type of analysis.15,16 Unfortunately, there is a
considerable lag period before these results have ther-
apeutic consequences and they do not allow immedi-
ate risk stratification at the time of diagnosis.
Hence, we examined whether gene expression pro-
files of leukemic bone marrow samples at diagnosis
could accurately predict subsequent risk group assign-
ment. It was not our intention to identify genes pre-
dicting the overall (long-term) outcome. In this study
we used oligonucleotide microarrays to evaluate bone
marrow aspirates from a total of 31 children.
Design and Methods
Patients and RNA preparation
A total of 31 children with ALL were included in the
study. Assignment to risk groups and treatment was
carried out according to the ALL-Berlin-Frankfurt-
Münster (BFM) 2000 protocol. In the ALL-BFM 2000
protocol, risk-adapted treatment stratification (stan-
dard-, intermediate-, or high-risk) is achieved using
cytogenetic markers (t(9;22), t(4;11)) or their molecular
counterparts (BCR-ABL and MLL-AF4) and the in vivo
response to treatment. Response is assessed cytomor-
phologically by the initial cytoreduction (blast reduc-
tion in peripheral blood after 7 days of treatment with
prednisone and one application of intrathecal
methotrexate; blast clearance from bone marrow after
induction therapy on treatment-day 33), or molecular-
ly by measurement of MRD on treatment-day 33 and
after induction consolidation at week 12. Further char-
acteristics of the patients are given in Table 1 and
Figure 1. Mononuclear cells (MNC) were obtained from
heparinized bone marrow (BM) at diagnosis and stored
frozen at –70°C within 24 h. Patients were enrolled
into the study if they had >75% leukemic blasts in the
BM. Total RNA was prepared from each sample by
extraction using a combined protocol of TRIZOL
(Invitrogen, Paisley, UK) and the RNeasy Mini kit
(Qiagen, Hilden, Germany). After lysis of the MNC in
TRIZOL, addition of chloroform, and centrifugation for
15 minutes at 4°C, the upper phase was mixed with
one volume of 70% ethanol and applied to an RNeasy
spin column, continuing with the RNeasy Mini kit pro-
tocol step 5 as described by the manufacturer. DNase
digestion was performed on column. Total RNA was
quantified and finally validated for integrity using the
Bioanalyzer 2100 (Agilent, Palo Alto, CA, USA).
Array hybridization and scanning
All experiments described in this study were per-
formed with the Affymetrix HG-U133A GeneChipTM,
containing 22,283 probe sets. Each GeneChipTM was
hybridized using targets synthesized from 100 ng
starting material (total RNA). Target synthesis,
hybridization, staining, and washing were performed
using standard protocols as recommended by the
manufacturer (Affymetrix, Santa Clara, CA, USA).
Because of the limited amount of RNA starting mate-
rial, we used the small sample labeling protocol, ver-
sion II (available from Affymetrix website,
http://www.affymetrix.com). Stained chips were
scanned on a Gene Array Scanner (Agilent, Palo Alto,
CA, USA), and data files were processed by GeneChipTM
software (Affymetrix, Santa Clara, CA, USA), to make
background and scaling corrections. All array data are
available from the ArrayExpress database (available at
URL http://www.ebi.ac.uk/arrayexpress).
Quantitative reverse transcription polymerase
chain reaction (RT-PCR)
We used quantitative RT-PCR to independently
determine the level of gene expression for 6 genes
(cyclin H, ribosomal protein large P0, ribosomal pro-
tein L34, ribosomal protein S19, neuritin 1, and tran-
scription factor-like 5) in eight randomly chosen sam-
ples. cDNA was generated from 500 ng of total RNA by
using the first strand step of the SuperScriptII kit
(Invitrogen, UK). PCR was carried out with the
ABI7700 (Applied Biosystems, Foster City, CA, USA)
using commercially available target probes and mas-
termix (Applied Biosystems, USA): CCNH-
Hs00236923_m1 (_at), RPLP0-Hs99999902_m1
(s_at), RPL34-Hs00241560_m1 (_at), RPS19-
Hs00357218_q1 (x_at), NRN1-Hs00213192_m1 (_at),
and TCFL5-Hs00232-4444_m1 (_at). We calculated
the CT values of each gene with the ABI sequence
detection system 1.9 program. (Applied Biosystems,
USA) and normalized them to the level of β2-
microglobulin (B2M-Hs99999907_m1). We obtained
correlation coefficients of 0.46, 0.94, 0.98, and 0.98
when correlating the TaqMan results to the expression
of the four specific (_at) probe sets of the GeneChip,
and 0.88, resp. –0.01, when correlating the real-time
RT-PCR results to the array data of the possibly unspe-
cific (s_at, resp. x_at) probe sets (see Supplemental
Figure A from URL http://www.kispi.unizh.ch/onkolo-
gie).
Statistical analysis
Clustering, supervised testing for differential expres-
sion and classification were done on base 10 log-
transformed expression data, using the statistical soft-
ware bundle R.17 Prior to an average-linkage hierarchi-
cal clustering of all 31 samples based on Euclidean
distances, we performed unsupervised gene filtering.18
By requiring a variation coefficient (SD/mean) of at
least 0.3 across samples and a minimal expression of
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20 absolute units in at least 16 of the 31 samples, we
obtained a set of 333 probe sets for the clustering.
Supervised testing for differential expression was done
by individually applying Welch's two sample t-test for
the whole set of 22,283 transcripts. Raw p values were
computed from a t-distribution with corresponding
degrees of freedom; they were then adjusted by the
Benjamini-Hochberg false discovery rate.19 The cut-off
for the adjusted p-values was set at 5%. The sub-
analysis of 5 standard-risk TEL-AML1 positive samples
versus 6 high-risk patients with a DNA index of 1 and
without further distinct cytogenetic alterations result-
ed in a set of 125 probe sets with significant differen-
tial expression. Among them, we identified 6 riboso-
mal proteins with specific probe sets, on which we
performed principal component analysis for dimension
reduction. The subsequent class prediction was per-
formed with 4 different methods: a support vector
machine with radial basis kernel, the 1-nearest neigh-
bor-rule, diagonal linear discriminant analysis and
logistic regression.20
Results
Visualization of gene expression profiles by
unsupervised hierarchical clustering
In order to establish gene expression profiles, we
analyzed bone marrow aspirates obtained at the time
of diagnosis from 31 children who were assigned to
risk classes according to the ALL-BFM 2000 protocol.
The series comprised 13 patients assigned to the stan-
dard-risk group, 8 patients to the intermediate group,
and 10 patients to the high-risk group (Table 1). In the
initial analysis of the gene expression data set, we
used an unsupervised hierarchical clustering algorithm
to arrange all 31 samples according to the similarity in
their expression patterns. This analysis grouped the
leukemia samples according to genetic and immuno-
Table 1. Patients’ characteristics and risk group assignment. 
Patient Sex Age Immunophenotype Cytogeneticsa Leukocytes Blasts Prednisone Risk
×109/L % (BM) Responseb groupc
1 M 6 y 1 mo. B precursor E2A-PBX1 66.5 83 good SR
2 F 6 y B precursor TEL-AML1 13.9 75 good SR
3 F 1 y 1 mo. B precursor normal 10.2 97 good SR
4 M 4 y 1 mo. B precursor TEL-AML1 3.0 89 good SR
5 M 3 y 6 mo. B precursor TEL-AML1 7.6 88 good SR
6 M 6 y 10 mo. B precursor TEL-AML1 2.9 98 good SR
7 F 6 y 8 mo. B precursor normal 45.9 98 good SR
8 M 2 y 3 mo. B precursor TEL-AML1 42.2 98 good SR
9 F 4 y 4 mo. T cell normal 101.0 95 good SR
10 M 12 y 8 mo. B precursor E2A-PBX1 18.3 >80 good SR
11 M 3 y 5 mo. B precursor normal 56.7 >80 good SR
12 F 3 y 7 mo. B precursor E2A-PBX1 20.4 >80 good SR
13 M 12 y 2 mo. B precursor E2A-PBX1 447.0 >80 good SR
14 M 5 y 7 mo. B precursor E2A-PBX1 17.1 96 good IR
15 M 2 y 11 mo. B precursor TEL-AML1 8.8 90 good IR
16 F 7 y 7 mo. B precursor hyper>50 8.8 99 good IR
17 M 6 y 9 mo. B precursor hyper>50 5.3 99 good IR
18 F 12 y B precursor normal 46.6 92 good IR
19 F 9 y 9 mo. T cell normal 56.1 87 good IR
20 M 1 y 8 mo. B precursor TEL-AML1 144.8 93 good IR
21 F 7 y 3 mo. B precursor normal 493.3 97 good IR
22 M 7 y B precursor BCR-ABL 24.4 92 good HR
23 M 2 y 11 mo. B precursor TEL-AML1 14.6 96 poor HR
24 M 6 y 4 mo. B precursor normal 7.0 95 good HR
25 F 2 y 3 mo. B precursor hyper>50 26.9 98 poor HR
26 F 8 y 1 mo. B precursor hyper>50 15.7 89 good HR
27 M 3 y 5 mo. B precursor normal 35.9 >80 good HR
28 M 1 y 1 mo. B precursor normal 91.8 >80 good HR
29 M 3 y 9 mo. B precursor normal 77.9 >80 poor HR
30 F 12 y 10 mo. B precursor normal 79.6 >80 poor HR
31 M 6 y B precursor normal 33.2 >80 poor HR
anormal indicates DNA index of 1, no TEL-AML1, BCR-ABL, E2A-PBX1, or MLL-AF4  rearrangement; bas defined by a reduction of leukemic blasts in the peripheral
blood to below 1000/mm3 after 7 days of  treatment with prednisone;  cSR indicates standard-risk, IR intermediate-risk, and HR high-risk.
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logical subtypes present in our series, namely 8
patients with TEL-AML1 rearrangement, 5 patients
with E2A-PBX1, 4 patients with hyperdiploid (>50)
chromosomes, and 2 with T-ALL (Figure 1). The two
patients with T-cell leukemia formed a separate
branch whereas samples with none of the above
defined karyotypic abnormalities were distributed over
the dendrogram. Interestingly, the t(1;19) was previ-
ously known to be present in only two patients.
However, unsupervised clustering grouped three more
patients (# 10, 12 and and 13) into the same branch.
These were then analyzed in a retrospective manner
for the E2A-PBX1 translocation by specific, quantita-
tive PCR and indeed found to be positive.21
To assess the quality of our data further and to veri-
fy the reproducibility of recently published data, we
identified those genes that are most strongly associat-
ed with the TEL-AML1 translocation (see Supplemental
Table A at http://www.kispi.unizh.ch/onkologie). Using
both the HG-U133A and B GeneChips, Ross et al. pub-
lished a gene list of classifiers of the top 100 χ2 probe
sets selected for TEL-AML1. Using Welch’s two sample
t-test, we identified 48% of these probe sets with
adjusted p-values below 5% within our data from HG-
U133A only (see Supplemental Table B from URL
http://www.kispi.unizh.ch/onkologie). Hence, despite
variation in the series of patients, labeling and statis-
tical processing, a high number of genes were found to
be identical in the published data and in our current
study.
Expression patterns associated with risk groups 
Our next goal was to identify genes whose expres-
sion levels best discriminate between patients in the
standard risk group as compared to those in the high-
risk group. We first used supervised testing to search
for genes that discriminated the 13 standard-risk
patients from the 10 high-risk ones. However, no genes
were found to have a significantly differential expres-
sion at the false discovery rate (FDR)-adjusted 5%-
level.
Thus, we focused on two cytogenetically more
homogeneous subgroups for screening risk-group dis-
criminatory genes, namely the 5 standard-risk TEL-
AML1 positive samples as well as the 6 high-risk sam-
ples with a DNA index of 1 and without further distinct
cytogenetic alterations. Supervised testing for differ-
ential expression using the t-test and p-values adjust-
ed by the FDR then revealed 125 probe sets with sig-
nificant expression differences (p < 0.05) (Figure 2, and
see Supplemental Table C from URL http://www.kispi.
unizh.ch/onkologie). We excluded that this comparison
is looking at the cytogenetic subtypes instead of the
overall risk group association, since 106 of the 125
Figure 1. Unsupervised hierarchical
clustering of gene expression data from
bone marrow samples of 31 children
with acute lymphoblastic leukemia.
Cluster dendrogram based on 333 fil-
tered probe sets (see methods for filter
criteria). The upper main branch
includes precursor B cell leukemias,
whereas the lowest branch identifies
two T-cell leukemias. The left column
shows the patient number, cytogenetic
characterization is listed in the middle
column, risk group assignment is pre-
sented in the right column. The dendro-
gram did not change substantially when
more (or even all) probe sets were used
(results not shown). *normal indicates
DNA index of 1 and no TEL-AML1, BCR-
ABL, E2A-PBX1 or MLL-AF4 rearrange-
ment.
29 normal* high
24 normal* high
8 TEL-AML1 standard
20 TEL-AML1 intermediate
6 TEL-AML1 standard
5 TEL-AML1 standard
15 TEL-AML1 intermediate
4 TEL-AML1 standard
23 TEL-AML1 high
2 TEL-AML1 standard
18 normal* intermediate
3 normal* standard
25 hyper > 50 high
16 hyper > 50 intermediate
17 hyper > 50 intermediate
26 hyper > 50 high
21 normal* intermediate
7 normal* standard
11 normal* standard
22 BCR-ABL high
31 normal* high
28 normal* high
30 normal* high
27 normal* high
1 E2A-PBX1 standard
14 E2A-PBX1 intermediate
13 E2A-PBX1 standard
10 E2A-PBX1 standard
12 E2A-PBX1 standard
9 T standard
19 T intermediate
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probe sets did not coincide with the genes discriminat-
ing all TEL-AML1 positive patients (n=8) from all sam-
ples without distinct cytogenetic alterations (n=13)
(see Supplemental Table D from URL
http://www.kispi.unizh.ch/onkologie; 19 probe sets also
appearing in Supplemental Table C are marked by an
asterix). About 75% of the selected probe sets showed
higher expression in high-risk samples. Remarkably,
these included a large number of genes coding for sev-
eral ribosomal proteins.
Risk group prediction by principal component
analysis
To test whether the expression of ribosomal proteins
can predict risk class assignment, the gene expression
data from all 31 children were analyzed. In a first step,
the 11 samples of the two cytogenetically homoge-
neous subgroups were projected into the space of the
first two principal components (PC) of the 6 ribosomal
proteins (with specific probe sets; _at) identified as
differentially expressed in the subanalysis (S27a, S29,
L18, L22, L24, L44; Figure 2). This showed that the risk
class assignment was clearly dependent on the riboso-
mal expression. The first two PC accurately discrimi-
nated the two subgroups (see Supplemental Figure B
from URL http://www.kispi.unizh.ch/onkologie). The
predominant effect in separating these groups came
from the first PC, which summarized 93.40% of the
total variation, whereas the second PC was of minor
importance, adding only a further 2.85% of the total
Figure 2. Gene signature associated with
risk groups. Top discriminating genes
between 5 TEL-AML1 positive patients
classified as standard-risk (SR TEL-AML1)
and 6 high-risk patients without distinct
cytogenetic alterations (indicated as HR
normal). Each column represents an indi-
vidual (n=11) and each row a probe set.
One hundred and twenty five probe sets
were identified using the t-test statistic
with an adjusted p value below 0.05 (left
heatmap). The 37 probe sets listed on the
right represent the specific probe sets
which do not reflect the cytogenetic
groups, but are specifically associated
with risk groups. The variation of absolute
expression values is displayed as a varia-
tion in color. The color scale extends from
–1.13 to 1.11 in log10 space as indicated
below the heatmap.
ribosomal protein L22
ribosomal protein S27a
ribosomal protein L44
ribosomal protein S29
ribosomal protein L24
ribosomal protein L18
cyclin H 
repressor of estrogen receptor activity
DKFZP434C171 protein
Consensus includes transcription factor AP2βb
Consensus  includes AL118510
hypotethical protein FLJ 13055
activating transcription factor 4
serine protease inhibitor, Kazal type, 2 (SPINK2)
hypotethical protein PRO1843
ATP synthetase, H+ transporting, mitochondrial F1, εe
excision repair cross-complementig deficiency6 (ERCC6)
solute carrier family 28, member 1 (CTN1a)
LBX1
rhoB
TYRO protein tyrosine kinase binding protein (DAP12)
dendritic cell protein GA17
estrogen-responsive B box protein
consensus includes rexo70
KIAA0692 protein
LRDD (Pidd)
hypothetical protein FLJ20154
KIAA0074 protein
ELK3
hypothetical protein FLJ13346
KIAA0635 gene product
hypothetical protein FLJ112121
consensus includes
AF056433.1
hypothetical protein FLJ10520
amyloid βb (a4) precursor protein
telomeric repeat binding factor 2
consensus includes AK026161.1
1.13 -0.46 0 0.44 1.11
SR TEL-AML1 HR normal
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variation. Next, we used this subanalysis group (n=11)
as training data and predicted the remaining stan-
dard-risk (n=8) and high-risk (n=4) samples with 4
different classifiers, each based on the first two PC as
the input. While the training data were perfectly sep-
arable, we observed between 5 and 7 misclassifica-
tions among the 12 samples of the cytogenetically less
homogeneous test set. The two-dimensional scatter-
plot in Supplemental Figure B (available from URL
http://www.kispi. unizh.ch/onkologie) shows the distri-
bution of all 31 samples, also including those from the
intermediate-risk patients.
To improve the classification, we tested several
combinations of additional genes from the list of 125
risk group discriminatory probe sets (Table 2). In this
way we excluded: genes that were associated specifi-
cally with the TEL-AML1 translocation (see supple-
mental Table D from URL http://www.kispi.unizh.ch/
onkologie) and genes that were represented by possi-
bly non-specific probe sets. From the remaining genes,
cyclin H and LRDD/Pidd were the two statistically best
discriminating genes between all standard- (n=13)
and all high-risk (n=10) patients (p=0.205, resp.
0.297). Hence, cyclin H, an important enzyme in cell
cycle control, and LRDD/Pidd, a gene involved in apop-
tosis, were tested for their predictive value as supple-
ment to the first ribosomal PC.22-24 Using four different
classification methods (namely a support vector
machine, the 1-nearest-neighbor rule, diagonal linear
discriminant analysis and logistic regression), we
found at best only 2 samples that were misclassified
among the 12 samples tested, i.e. ten samples were
assigned to the correct risk group currently used in the
clinic, already at the time of diagnosis (Figure 3). This
corresponds to a specificity of 83.3%. We also
obtained only 2 misclassifications if cyclin H and
LRDD/Pidd were tested alone. In contrast, a prediction
using all 125 probe sets yielded at least 7 misclassifi-
cations and therefore was much worse than using the
selected probe sets described above.
Discussion
Genome-wide expression patterns are able to identi-
fy immunological subgroups (precursor-B ALL versus T-
cell leukemia) and cytogenetic abnormalities such as
TEL-AML1, E2A-PBX1, BCR-ABL, hyperdiploid karyotype
with >50 chromosomes, and MLL gene rearrangements
in childhood ALL with high accuracy.6-11 In contrast,  no
studies have been carried out that describe gene
expression signatures related to the initial risk group
Table 2. Classification errors using different statistical
methods. Numbers depict misclassified samples from
12 test samples.
Probe sets SVMa NNRb DLDAc LRd
125 selected probe sets 8 7 7 7
ribosomal (1.PC)e 6 6 7 7
cyclin H 3 3 3 3
LRDD/Pidd 4 4 4 4
1.PC & cyclin H 4 6 3 4
1.PC & LRDD/Pidd 4 6 4 4
LRDD/Pidd & cyclin H 2 2 3 3
1.PC & cyclin H & 3 3 3 2
LRDD/Pidd
asupport vector machine; b1-nearest-neighbor rule; cdiagonal linear discriminant
analysis; dlogistic regression; efirst principal component (PC) of the 6 specific
ribosomal probe sets.
Figure 3. Risk group prediction by selected signature genes. Three-dimensional scatterplots with three predictor
variables; the first PC of 6 ribosomal proteins (S27a, S29, L18, L22, L24, L44; x-axis), cyclin H (y-axis) and
LRDD/Pidd (z-axis). The left panel shows standard-risk TEL-AML1 positive samples (n=5, blue) and high-risk patients
without distinct cytogenetic alterations (n=6, red). The right panel shows all 31 samples; blue: standard-risk; yel-
low: intermediate-risk; red: high-risk.
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stratification. Based on strict quality parameters, we
established expression profiles of 31 patients (see
Supplemental Table E from URL  http://www.kispi.
unizh.ch/onkologie). Despite the rather small study
group, all distinct subgroups of ALL occuring in children
older than one year (except MLL rearrangements which
are rare in this group of patients) are represented in our
series of patients.  Analyzing the microarray data of the
entire study group, no gene could be identified that
was capable of discriminating clearly between all stan-
dard- and all high-risk patients. This is most likely due
to the cytogenetic heterogeneity in the two risk groups.
In addition, a variety of other risk-related factors, such
as sex, age, and leukocyte count, might have prevented
a distinct signature from being identified. As a third
aspect, we only analyzed expression data established
with the HG-U133A GeneChipTM; other more complex
microarrays would, perhaps, reveal different results. 
Nevertheless, when we screened for risk-related
genes by focusing on more homogeneous subgroups,
we identified a combination of single genes whose
expression is associated with either a standard- or a
high-risk classification with an accuracy of over 80%.
Although these genes were initially identified in asso-
ciation with TEL-AML1 samples, their expression pat-
tern was correlated with risk group independently of
the cytogenetic subtype. This finding is further sup-
ported by analysis of TEL-AML1 specific signatures
defined in two recent studies with a very large group of
patients.10,11 None of our final classifier genes can be
found in the TEL-AML1 characterizing gene lists.
Using different statistical methods, the genes identi-
fied, namely genes for 6 ribosomal proteins, cyclin H,
and LRDD/Pidd, correctly predicted risk group assign-
ment for 10 out of 12 cytogenetically heterogeneous
samples. The 2 misclassified samples were from stan-
dard-risk patients but, according to the expression of
our predictor genes, were apparently associated with a
high risk. One of these samples (# 12) was inconspicu-
ous with a translocation t(1;19). In contrast, it is inter-
esting to note that the other sample (# 11), clustered in
the unsupervised hierarchical analysis, most closely to
the one sample expressing BCR-ABL, which by this fact
had been assigned to the high-risk group. Hence, our
analysis suggests that the risk group assignment and
further course of disease evolution of patient #11
should be monitored particularly closely during follow-
ing treatment periods. Unsurprisingly, we were not able
to define a distinct expression profile or to subclassify
the patients in the intermediate-risk group further,
since the intermediate group comprises all samples not
classified in either the standard- or the high-risk group,
and is very heterogeneous. Nevertheless, most samples
from this group were placed closer to those from stan-
dard-risk patients. Expression profiles, as a single plat-
form, will probably not be able to refine their classifi-
cation significantly.
Differential expression of ribosomal genes in cancer
has been discussed in several studies.25 Upregulation of
transcripts for ribosomal proteins has been shown in
several malignancies, including carcinoma of the colon,
rectum, prostate, and esophagus.26-28 Contrariwise, some
authors have described that ribosomal proteins are
downregulated in more aggressive subtypes of cancer
compared to more favorable subtypes; this effect has
been reported for carcinoma of the ovary, breast cancer
and chronic lymphocytic leukemia.29-31 In our study we
observed upregulation of the expression of ribosomal
proteins in childhood ALL patients with an unfavorable
outcome. In addition, two single genes were found to
be associated with risk group: cyclin H and LRDD/Pidd.
Cyclin H was upregulated in the high-risk samples and,
as part of the general transcription factor TFIIH com-
plex, is clearly involved in cell cycle regulation.23 The
other gene,  LRDD/Pidd, was expressed at higher levels
in standard-risk patients; its significance is less well
understood. Its murine homolog, Pidd, can be regulated
by p53 and seems to be able to promote apoptosis.24
However, functional studies are needed to define the
role of these genes in childhood ALL. 
Our results provide an initial assessment of risk-asso-
ciated gene expression in childhood ALL. Considering all
low- and high-risk patients, no gene was capable of
predicting the risk assignment already at diagnosis.
Nevertheless, we report a classifier of 3 predictor vari-
ables that could predict current risk assignment with
an accuracy rate of more than 80% in an independent
test set. Despite these findings, our results suggest that
gene expression profiling cannot predict final risk strat-
ification accurately and independently from various
other risk-related factors. Further investigations aimed
at identifying a signature with a stronger predictive
value, by using a larger, homogeneous group of
patients, seem to be warranted. 
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